Evidence map›Paper›PMID 34427763›Full record

ArticleApplied microbiology and biotechnology2021

Novel peptide (RATH) mediated delivery of peptide nucleic acids for antiviral interventions.

Vinay G Joshi, Kantaraja Chindera, Manish V Bais, Basavaraj Sajjanar, Ashok K Tiwari, Satish Kumar

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Recent Cutting-Edge Technologies for the Delivery of Peptide Nucleic Acid.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Vinay G JoshiCentral Instrumentation Facility (CIF), Department of Veterinary Biotechnology, Indian Veterinary Research Institute (IVRI), Bareilly, UP, 243122, Izatnagar, India.
Kantaraja ChinderaCentral Instrumentation Facility (CIF), Department of Veterinary Biotechnology, Indian Veterinary Research Institute (IVRI), Bareilly, UP, 243122, Izatnagar, India.
Manish V BaisDepartment of Translational Dental Medicine, School of Dental Medicine, Boston University Boston, Boston, USA.
Basavaraj SajjanarCentral Instrumentation Facility (CIF), Department of Veterinary Biotechnology, Indian Veterinary Research Institute (IVRI), Bareilly, UP, 243122, Izatnagar, India.
Ashok K TiwariMolecular Biology Lab, Department of Veterinary Biotechnology, Indian Veterinary Research Institute (IVRI), Bareilly, UP, 243122, Izatnagar, India.
Satish KumarCentral Instrumentation Facility (CIF), Department of Veterinary Biotechnology, Indian Veterinary Research Institute (IVRI), Bareilly, UP, 243122, Izatnagar, India. drsatishkumar_ivri@yahoo.co.in.ORCID http://orcid.org/0000-0001-8872-1838
Indian Veterinary Research Institute · INBoston University · US

Funding

Department of Biotechnology, Government of India BT/PR11271/MED/32/81
6 · The paper itself

Abstract

The peptide nucleic acid (PNA) is a chimeric molecule with the nucleobases connected by peptide bonds. This chimeric nature gives the PNA certain therapeutic advantages over natural antisense nucleic acid molecules. The PNA probes are known for its better and stronger complementation with target nucleic acids. However, cellular delivery of PNA is a major hurdle due to the charge-neutral nature of the PNA. For cellular delivery of PNA, peptide-PNA conjugates are used. This approach may face some practical limitation in terms of PNA antisense activity. In this study, we propose a novel RATH-2 peptide-based non-covalent PNA delivery mechanism. We observed RATH-2 shows a favorable molecular interaction with PNA at 16:1 (peptide:PNA) molar ratio resulting in co-centric nanoparticle formation. With this combination, we could achieve as high as 93% cellular delivery of the PNA. The proposed non-covalent RATH:PNA delivery model showed endocytic entrapment free delivery of PNA. The study further demonstrated the therapeutic application of PNA with in vitro antiviral intervention model. Using RATH-2 non-covalent PNA delivery system, we could inhibit 69.5% viral load. The present study demonstrates a cell-penetrating peptide:PNA interaction can lead to nanoparticle formations that facilitated cellular delivery of PNA.Key points• A novel cell-penetrating peptide (RATH-2) was identified for non-covalent delivery of PNA.• RATH-2 and PNA formed co-centric nanoparticles at appropriate molar combination.• PNA delivered through the RATH-2 inhibited the viral gene expression and reduced the viral load.

Indexed as

Cell-Penetrating PeptidesNanoparticlesPeptide Nucleic AcidsAntiviral AgentsOligonucleotides, AntisenseAntiviral AgentsCell-Penetrating PeptidesOligonucleotides, AntisensePeptide Nucleic AcidsAntiviral PNACell-penetrating peptideNon-covalent deliveryPeptide nucleic acid

Identifiers

PMID34427763
OpenAlexW3194786634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.